

Home | SAGE Clinical Study | GelrinC | Information about Study Sites | About the knee | FAQs | Study Investigators | Study Patients

SAGE Clinical Study by Regentis Biomaterials

GelrinC Technology

Researchers at Regentis Biomaterials have developed an investigational implant called GelrinC, which is intended to fill the cartilage defect and create an environment for organized repair by the body.

GelrinC is composed of a synthetic material called PEG-DA and a structurally modified (denatured) protein called fibrinogen. These two materials have been used separately in medical products for other conditions but in GelrinC are used together for cartilage repair.



GelrinC Procedure

GelrinC is applied to the cartilage defect as a liquid and is then exposed to UVA light for 90 seconds. As a result, it turns into a solid, soft implant, completely occupying the space of the defect.



Cartilage defect

Liquid GelrinC

Liquid GelrinC transforms into solid implant following 90 seconds exposure to UVA light

Transparent GelrinC

with microfracture holes

application to the defect using a syringe implant in the defect

NOTE: For simplicity, only basic illustrations of the GelrinC procedure are presented. Accessory devises used during the procedure are not shown.



How does GelrinC repair knee cartilage?

GelrinC is a new implant which fills the defect in the cartilage in your knee and may create an environment for organized repair by the body. GelrinC is intended to be gradually resorbed by the body over a period of 6-9 months and replaced by new, healthy cartilage tissue. The SAGE Study will determine if this is true and whether the newlygrown cartilage is of similar strength and durability as healthy cartilage.



CAUTION: Investigational Device. Limited by Federal (USA) Law to Investigational Use.



© Copyright 2018 Regentis Biomaterial Ltd. All rights reserved | About Regentis | Terms of Use | Privacy Policy | Version: February 2018